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Amyloid-beta and tau synergistically impair the oxidative
phosphorylation system in triple transgenic Alzheimer's disease
mice
Abstract
Alzheimer's disease (AD) is characterized by amyloid-beta (Abeta)-containing plaques, neurofibrillary
tangles, and neuron and synapse loss. Tangle formation has been reproduced in P301L tau transgenic
pR5 mice, whereas APP(sw)PS2(N141I) double-transgenic APP152 mice develop Abeta plaques.
Cross-breeding generates triple transgenic ((triple)AD) mice that combine both pathologies in one
model. To determine functional consequences of the combined Abeta and tau pathologies, we performed
a proteomic analysis followed by functional validation. Specifically, we obtained vesicular preparations
from (triple)AD mice, the parental strains, and nontransgenic mice, followed by the quantitative
mass-tag labeling proteomic technique iTRAQ and mass spectrometry. Within 1,275 quantified proteins,
we found a massive deregulation of 24 proteins, of which one-third were mitochondrial proteins mainly
related to complexes I and IV of the oxidative phosphorylation system (OXPHOS). Notably,
deregulation of complex I was tau dependent, whereas deregulation of complex IV was Abeta
dependent, both at the protein and activity levels. Synergistic effects of Abeta and tau were evident in
8-month-old (triple)AD mice as only they showed a reduction of the mitochondrial membrane potential
at this early age. At the age of 12 months, the strongest defects on OXPHOS, synthesis of ATP, and
reactive oxygen species were exhibited in the (triple)AD mice, again emphasizing synergistic,
age-associated effects of Abeta and tau in perishing mitochondria. Our study establishes a molecular
link between Abeta and tau protein in AD pathology in vivo, illustrating the potential of quantitative
proteomics.
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Alzheimer’s disease (AD) is characterized by amyloid-beta (A)-
containing plaques, neurofibrillary tangles, and neuron and syn-
apse loss. Tangle formation has been reproduced in P301L tau
transgenic pR5 mice, whereas APPswPS2N141I double-transgenic
APP152 mice develop A plaques. Cross-breeding generates triple
transgenic (tripleAD) mice that combine both pathologies in one
model. To determine functional consequences of the combined A
and tau pathologies, we performed a proteomic analysis followed
by functional validation. Specifically, we obtained vesicular prep-
arations from tripleAD mice, the parental strains, and nontransgenic
mice, followed by the quantitative mass-tag labeling proteomic
technique iTRAQ and mass spectrometry. Within 1,275 quantified
proteins, we found a massive deregulation of 24 proteins, of which
one-third were mitochondrial proteins mainly related to complexes
I and IV of the oxidative phosphorylation system (OXPHOS).
Notably, deregulation of complex I was tau dependent, whereas
deregulation of complex IV was A dependent, both at the protein
and activity levels. Synergistic effects of A and tau were evident
in 8-month-old tripleAD mice as only they showed a reduction of the
mitochondrial membrane potential at this early age. At the age of
12 months, the strongest defects on OXPHOS, synthesis of ATP, and
reactive oxygen species were exhibited in the tripleAD mice, again
emphasizing synergistic, age-associated effects of A and tau in
perishing mitochondria. Our study establishes a molecular link
between A and tau protein in AD pathology in vivo, illustrating
the potential of quantitative proteomics.
amyloid-beta peptide  electron transport chain  energy metabolism 
mitochondrial complexes  tau protein
A lzheimer’s disease (AD) is a devastating neurodegenerativedisorder affecting 15 million people worldwide (1). The
key histopathological features are amyloid-beta (A)-containing
plaques and microtubule-associated protein tau-containing neu-
rofibrillary tangles (NFTs), along with neuronal and synapse loss
in selected brain areas (2, 3). In determining the role of distinct
proteins in these processes, traditionally, candidate-driven ap-
proaches have been pursued, linking neuronal dysfunction to the
distribution of known proteins in healthy compared with degen-
erating neurons, or in transgenic compared with control brain.
In comparison, proteomics offers a powerful nonbiased ap-
proach as shown by us previously (4, 5).
APP152 (APP/PS2) double-transgenic mice model the A
plaque pathology of AD (6); they coexpress the N141I mutant
form of PS2 together with the APPsw mutant found in familial
cases of AD. The mice display age-related cognitive deficits
associated with discrete brain A deposition and inflammation
(6). pR5 mice model the tangle pathology of AD (7–9). They
express P301L mutant tau found in familial cases of frontotem-
poral dementia (FTD), a dementia related to AD. The pR5 mice
show a hippocampus- and amygdala-dependent behavioral im-
pairment related to AD (10). Crossing of pR5 andAPP/PS2mice
revealed that total tau and APP levels, respectively, were not
altered in tripleAD mice, suggesting that there is no titration of
transcription factors for the promoters driving either mutant
APP or tau transgene expression (11). Of particular relevance in
the tripleADmice is the low interanimal variability and early onset
of tau pathology (11).
Here, we performed a comparative, quantitative proteomic
analysis of single-transgenic pR5, double-transgenic APP/PS2,
and tripleAD (pR5/APP/PS2) mice, as well as wild-type controls,
and found that one-third of the deregulated proteins were
mitochondrial. In evaluating our findings, we could establish
mitochondrial dysfunction in tripleAD mice, synergistically in-
duced by tau and A pathologies.
Results
Comparative iTRAQ (Isobaric Tags for Relative and Absolute Quanti-
tation) Mass Spectrometry. Crude vesicular fractions of forebrains
obtained from 10-month-old single-transgenic pR5 mice, dou-
ble-transgenic APP/PS2 mice, a cross of the 2 strains (tripleAD),
and nontransgenic littermate controls were trypsin digested (n
6 animals for each group), and peptides labeled with iTRAQ.
Then, these were separated by HPLC, using both reverse-phase
(RP) and strong cation exchange (SCX) columns, followed by
nanoLC-ESI MS/MS mass spectrometry (3 iTRAQ runs and 4
two-dimensional LC ESI MS/MS data sets were used to obtain
iTRAQ data). Data processing identified 1,598 proteins, 1,539 of
which were quantified; 1,275 with more than 2 peptides. Twenty-
four proteins were found to be differentially expressed in tripleAD
compared with the other samples (Table 1 and Table S1).
Deregulated Proteins Identified by iTRAQ. ProteinPilot requires a
minimum of 40 counts of iTRAQ reporting ion intensities to
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calculate iTRAQ ratios. Proteins identified with iTRAQ tag ion
intensities below this threshold were not quantified. In our study,
90% of the identified proteins had iTRAQ ratios (Fig. S1A),
and of these, 80% were calculated from more than 2 peptides.
We tabulated iTRAQ ratios of all proteins using the tripleAD
as denominator and iTRAQ ratios 1.2 or 0.82 with a P value
0.01 as threshold to identify deregulated proteins as listed in
Table 1. A protein had to show the same deregulation trend in
at least 2 of the 3 runs to be considered as deregulated. From our
past experience iTRAQ ratios 1.2 or 0.82 with a P value
0.01 indicate protein differences of at least 1.5-fold.
Consistent with transgenic tau expression, the experimental
data show that tau is significantly up-regulated in pR5 mice and
tripleAD mouse brain compared with wild-type and APP/PS2
mice. We performed an overrepresentation analysis using the
Gene Ontology (GO) database to perform a functional charac-
terization of the deregulated proteins and established a GOmap
as described in ref. 12. This revealed that one-third of the
proteins have functions in mitochondria, specifically complex I
and IV (Table 1). In agreement, separation of mitochondrial
complexes from cortical brain by 2D resolution confirmed a
similar deregulation of the 49-kDa subunit of complex I and
subunits II and IV of complex IV (Fig. S1 B and C). Therefore,
we decided to assess tripleAD compared with pR5 and APP/PS2
mice for mitochondrial function.
TripleAD Mice Exhibit Strong Defects in Mitochondrial OXPHOS, Com-
plex Activities, and Energy Homeostasis. A high-resolution respira-
tory system has been used to evaluate the capacity of the entire
oxidative phosphorylation system (OXPHOS) of cerebral mito-
chondria from the 4 mouse strains (Fig. 1A). We determined flux
control ratios to obtain information on metabolic states of
respiration. The respiratory control ratio (RCR3/4) is an indi-
cator of the state of coupling of mitochondria. State 3 is the rate
of phosphorylating respiration in the presence of exogenous
ADP, and state 4 is associated with proton leakage across the
inner mitochondrial membrane in the absence of ADP. Our
findings suggest a pronounced decrease of RCR3/4 in mitochon-
dria from APP/PS2 and tripleAD compared with age-matched
wild-type mice (Fig. 1B). When we examined the ETS/ROX
(electron transport system/residual oxygen consumption) ratio,
which yields an index of the maximum oxygen consumption
capacity relative to the magnitude of residual oxygen consump-
tion, we found that it was also decreased in APP/PS2 and tripleAD
compared with age-matched wild-type mice (Fig. 1C). We have
shown previously that respiration of mitochondria from pR5
mice is reduced compared with wild-type controls, but not until
the age of 24 months (4) (Fig. S2). In contrast, APP/PS2
mitochondria showed a decrease in OXPHOS compared with
wild-type already at the age of 8 months (Fig. 1D). At this age,
OXPHOS of brain mitochondria from tripleAD mice did not
differ compared with that of age-matched APP/PS2 mitochon-
dria (Fig. 1E), but it was significantly decreased in tripleAD mice
at the age of 12 months (Fig. 1 F and G). Taken together, with
increasing age, the global failure of the mitochondrial respira-
tory capacity deteriorated the strongest in mitochondria from
Table 1. iTRAQ ratios (wild-type vs. tripleAD, pR5 vs. tripleAD, and APP/PS2 vs. tripleAD) showing differentially expressed proteins
observed by iTRAQ experiment
Accession no. Name
Wild-type vs.
tripleAD
pR5 vs.
tripleAD
APP/PS2 vs.
tripleAD
ANXA5MOUSE (P48036) Annexin A5 (Annexin V) (Lipocortin V) 1.28 0.63
ANXA6MOUSE (P14824) Annexin A6 (Annexin VI) (Lipocortin VI) 1.46 2.2
ARF3MOUSE (P61205) ADP-ribosylation factor 3 0.65
BASPMOUSE (Q91XV3) Brain acid soluble protein 1 (BASP1 protein) 1.51
CALMMOUSE (P62204) Calmodulin (CaM) 0.78 0.65
COX2MOUSE (P00405) Cytochrome c oxidase subunit 2 (EC 1.9.3.1) 1.22 1.42
COX41MOUSE (P19783) Cytochrome c oxidase subunit IV isoform 1, mitochondrial
precursor (EC 1.9.3.1)
1.36 1.47
COX5AMOUSE (P12787) Cytochrome c oxidase polypeptide Va, mitochondrial precursor
(EC 1.9.3.1)
1.21 1.43
COX5BMOUSE (P19536) Cytochrome c oxidase polypeptide Vb, mitochondrial precursor
(EC 1.9.3.1)
1.33
CX7A2MOUSE (P48771) Cytochrome c oxidase polypeptide VIIa-liver/heart, mitochondrial
precursor (EC 1.9.3.1)
1.41 1.69
HBAMOUSE (P01942) Hemoglobin alpha subunit 0.73 0.69
HBB1MOUSE (P02088) Hemoglobin beta-1 subunit chain 0.69 0.6
MBPMOUSE (P04370) Myelin basic protein (MBP) (Myelin A1 protein) 1.32 1.22
NDKAMOUSE (P15532) Nucleoside diphosphate kinase A (EC 2.7.4.6) 0.56
NIDMMOUSE (Q9DCS9) NADH-ubiquinone oxidoreductase PDSW subunit (EC 1.6.5.3) 1.39 0.66
NUCMMOUSE
(Q91WD5)
NADH-ubiquinone oxidoreductase 49 kDa subunit, mitochondrial
precursor (EC 1.6.5.3)
0.8
NUIMMOUSE (Q8K3J1) NADH-ubiquinone oxidoreductase 23 kDa subunit, mitochondrial
precursor (EC 1.6.5.3)
1.22
PHBMOUSE (P67778) Prohibitin (B-cell receptor associated protein 32) (BAP 32) 0.77
PPIAMOUSE (P17742) Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8) 1.4
S12A2MOUSE (P55012) Solute carrier family 12 member 2 symporter) 1.49
SYN2MOUSE (Q64332) Synapsin-2 (Synapsin II) 1.69
TAUMOUSE (P10637) Microtubule-associated protein tau (Neurofibrillary tangle protein) 0.64 0.6
THY1MOUSE (P01831) Thy-1 membrane glycoprotein precursor 1.4 1.94
VA0DMOUSE (P51863) Vacuolar ATP synthase subunit d 1.35 1.71 0.77
Wild-type and tripleAD mouse samples are compared to other types. Only iTRAQ ratios satisfying the criterion (P value  0.01 and 0.82  iTRAQ ratio  1.2)
with the same ratio-changing trends in a minimum of 2 of the 3 independent iTRAQ runs and not having ratio-changing trends in any other runs are listed.
Deregulated subunits of complexes I and IV are bold.
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tripleAD mice, suggesting a synergistic destructive effect of tau
and A on mitochondria.
Next, we used a direct measurement of the specific activity of
complex I in freshly isolated brain mitochondria, i.e., NADH-
ubiquinone oxidoreductase activity measured as NADH:DBQ ac-
tivity that was then normalized to complex I content (NADH:HAR
activity). At 8months, complex I activity was only decreased in pR5
mice, confirming our previous data about complex I deficiency in
thesemice (4) (Fig. 2A). At 12months of age, all 3 transgenicmouse
models exhibited a significant decrease of DBQ/HAR compared
withwild-typemice (Fig. 2A). Interestingly, at the age of 12months,
content of complex I (measured by HAR activity) was increased in
tripleADmice, suggesting a compensatory up-regulation in response
to functional deficits of this complex (Fig. S3). Similarly, compared
with APP/PS2 mice, complex I proteins were found to be up-
regulated (Table 1). Activity of citrate synthase (CS), a pace-
making enzyme in the first step of the Krebs cycle, thought to be
proportional to the content of OXPHOS enzymes (13), was in-
creased in 8-month-old APP/PS2 and tripleAD mice. At 12 months,
the increase persisted only in cortical mitochondria from tripleAD
mice, suggesting a compensatory incapacity to restore a physiolog-
ical state specifically in this mouse model that exhibits the strongest
AD pathology of both plaques and tangles (Fig. 2B).
At the age of 8 months, APP/PS2 and tripleAD mice showed a
significantly decreased complex IV activity (CIV/CS ratio) (Fig.
2C). This decrease becamemoremarked at the age of 12 months,
when the accumulation of defects in the single complexes as well
as in the entire OXPHOS, respectively, could not be further
compensated as shown by a drop in ATP levels in cortical brain
cells from APP/PS2 and tripleAD mice, with the strongest de-
crease seen in the latter (Fig. 2D). This indicates a general
disturbance of cellular energy homeostasis in the cortices of
these mice. The effect was brain region-specific as no difference
in ATP levels was observed in cerebellar cells from the same
mice (Fig. S4).
A and Hyperphosphorylated Tau Cause a Decreased Mitochondrial
Membrane Potential (MMP). Based on our recent in vitro results
that cortical brain cells from pR5 mice are particularly sensitive
to synthetic A insult (14, 15), we determined the mitochondrial
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Fig. 1. High-resolution respiratory system reveals a heightened defect in the mitochondrial OXPHOS from brains of tripleAD mice. Measurement of oxygen (O2)
flux and consumption in freshly isolated mitochondria from cortical brains of age-matched wild-type, APP/PS2, and tripleAD mice. After detection of endogenous
respiration (mito), glutamatemalate (g/m) were added to induce state 4 respiration. ADP stimulated state 3 respiration. After determining coupled respiration,
FCCP was added and the maximal respiratory capacity measured in the absence of a proton gradient. Cytochrome c (cyt c) demonstrated mitochondrial membrane
integrity. To inhibit activities of complexes I–III, rotenone (rot) and antimycine A (AA) were added. Complex IV activity was stimulated by ascorbate/TMPD (A/T)
before terminating mitochondrial respiration by adding sodium azide (azide). O2 consumption was normalized to the corresponding citrate synthase (CS) activity.
(A) Representative diagrams of O2 flux and consumption in mitochondria from 12-month-old wild-type, APP/PS2, and tripleAD mice in response to titrated
substrates and inhibitors of mitochondrial complexes. (B) RCR3/4 (state3/state4 ratio) representing the mitochondrial coupling state was reduced in 8- and
12-month-old APP/PS2 and tripleAD mice. (C) ETS/ROX ratio, which yields an index of the maximum oxygen consumption capacity of the electron transport system
(ETS) relative to the magnitude of residual oxygen consumption (ROX), was reduced in 8- and 12-month-old APP/PS2 and tripleAD mice compared with
age-matched wild-type mitochondria. (D) Two-way ANOVA revealed a significant effect of the transgene on the respiratory rates of mitochondria between
8-month-old wild-type and APP/PS2 mice (P  0.001). (E) No difference was observed in respiration between 8-month-old APP/PS2 and tripleAD mice. (F) At 12
months of age, respiration differed again significantly between wild-type and APP/PS2 (P 0.001) and (G) between APP/PS2 and tripleAD mice (P 0.001). (B and
C) One-way ANOVA post hoc Tukey’s. (D–G) Two-way ANOVA post hoc Bonferroni. *, P 0.05; **, P 0.01; ***, P 0.001 vs. wild-type; , P 0.01; , P
0.001 vs. APP/PS2 (n  7–12 animals/group).
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membrane potential (MMP) that is widely considered as an
indicator of mitochondrial functionality (16). Basal MMP was
significantly and exclusively reduced in cortical cells from
8-month-old tripleAD mice. At 12 months, MMP was additionally
reduced in cortical cells from APP/PS2 mice (Fig. 3A). Impor-
tantly, the same results were obtained using a different fluores-
cent dye (R123; Fig. S5). Again, this effect was brain region-
specific as it was not observed for the cerebellum (Fig. S6).
IncreasedMitochondrial Failure Is Accompanied by Enhanced Reactive
Oxygen Species (ROS) Production. Superoxide anion levels were
enhanced in cortical brain cells of 12-month-old APP/PS2 mice
and markedly increased in those of age-matched tripleAD mice
(Fig. 3B). In addition, cytosolic ROS levels were enhanced in
brain cells from APP/PS2 and tripleAD mice (Fig. 3C). These
differences were only observed at an age of 12, and not 8 months
(Fig. S7 A and B), suggesting that at the older age, brain
mitochondria are not capable of compensating their respiratory
failure.
Discussion
Energy deficiency and mitochondrial dysfunction have been
recognized as a prominent, early event in AD, but the mecha-
nisms leading to mitochondrial failure are not well understood
(15, 17–24). Recently, we had shown in vivo that P301L mutant
tau was capable of inducing mitochondrial dysfunction and
increasing levels of ROS in pR5 mice (4). We had also found an
increased mitochondrial vulnerability of pR5 cortical brain cells
toward A in vitro (4, 14). However, the relative contribution of
tau and A remained unclear, as did possible synergistic effects.
To address this, we investigated brains of pR5, APP/PS2, and
tripleAD (pR5/APP/PS2) mice, the latter combining A and tau
pathologies.
In the present study we could clearly show that with increasing
age, both A and tau synergistically impair mitochondrial func-
tion and energy homeostasis in vivo. At 8 months of age, in
agreement with previous data (4), complex I activity was only
decreased in pR5, and not in APP/PS2 and tripleAD mice,
indicating a tau-specific sensitivity of complex I of OXPHOS. In
contrast, activity of CS, a pace-making enzyme of the Krebs
cycle, was increased in 8-month-old APP/PS2 and tripleAD mice.
At this age, a robust cortical pathology of A plaques and tau
deposits is present (11). Because CS activity seems to be
proportional to the content of enzymes of OXPHOS (13), the
increased activity can be interpreted as compensatory mecha-
nism of mitochondria in response to OXPHOS failure, a mech-
anism initiated in tripleAD mice already at the age of 4 months,
when A accumulation and abnormal tau phosphorylation (such
as of epitope T231) become evident (11). Notably, at this early
age, cortical brain cells from tripleAD mice exhibit already a
tendency to reducedMMP, suggesting that this is a very sensitive
indicator of early mitochondrial failure. The decrease in MMP
(that was not seen in the parental strains) further continued until
tripleAD mice reached 8 months of age, emphasizing a synergistic
action of A and tau. At 12 months, increased A levels per se
were able to reduce MMP, because a significant reduction was
present also in APP/PS2 mice, but the reduction of MMP was
more pronounced in tripleAD mice.
Complex IV activity was decreased in APP/PS2 and tripleAD
cortices at 8 months of age, but not in pR5, confirming related
findings that it is mainly the A pathology that affects complex
IV activity, both in vivo and in vitro (22, 25). In APP/PS2
compared with wild-type mice, an impairment of OXPHOS as
detected by decreased oxygen consumption was seen at this age,
suggesting an earlier and stronger effect of the A/APP pathway
on this vulnerable mitochondrial system compared with tau, as
oxygen consumption of pR5 mitochondria was reduced, but not
until the mice reached 24 months of age (4). Similarly, both flux
control ratios RCR3/4 and ETS/ROX, which measure metabolic
states of mitochondrial respiration, were similarly decreased in
APP/PS2 and tripleAD mitochondria, indicating an A-induced
increase of the uncoupling state of these organelles. The data
indicate that A affects mitochondrial function more extensively
and at different levels of respiration and function than tau does,
which only shows an early effect on the activity of a single
complex of OXPHOS, but evidently increases the vulnerability
to A toxicity in vivo. Notably, at 8 months, no change in cellular
wild-type APP/PS2 tripleADpR5
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Fig. 2. Impaired mitochondrial enzyme activities and decreased ATP levels in
cortical brain cells from tripleAD mice. (A) Complex I activity (DBQ/HAR ratio)
was decreased in 8-month-old pR5 mitochondria. At 12 months, all 3 trans-
genic mouse models presented a decrease in complex I activity. (B) Citrate
synthase (CS) activity was increased in 8-month-old APP/PS2 and tripleAD mice.
At 12 months, the increase persisted only in tripleAD mice. (C) Complex IV
activity (CIV/CS ratio) was decreased in APP/PS2 and tripleAD mitochondria at 8
months of age. The decrease became more pronounced at the age of 12
months. (D) ATP levels were reduced in 12-month-old APP/PS2 and triple mice.
(A–D) One-way ANOVA post hoc Tukey’s. *, P  0.05; **, P  0.01; ***, P 
0.001 vs. wild type; , P  0.05 vs. pR5 (n  7–12 animals/group).
A
0
50
100
150
200
250
300
350
g
m
 /
 sti
n
u
 ER
MT
ni
et
orp
4 months 8 months 12 months
*
*
**
0
2
4
6
8
10niet
orp
 g
m
 /
 sti
n
u
 FC
D
12 months
C
* **
++
0
1
2
3niet
orp
 g
m
 /
 sti
n
u
 EH
D
B
12 months
***
wild-type APP/PS2 tripleADpR5
Fig. 3. Reduced MMP and increased ROS levels in cortical brain cells from
tripleAD mice. (A) MMP (TMRE fluorescence units/mg protein) was reduced in
cortical cells from 8-month-old tripleAD mice. At the age of 12 months, MMP
was also reduced in cells from APP/PS2 mice. (B) Levels of superoxide anion
radicals (DHE fluorescence units/mg protein) and (C) cytosolic ROS (DCF fluo-
rescence units/mg protein) were increased in cells from 12-month-old APP/PS2
and tripleAD mice. (A–C) One-way ANOVA post hoc Tukey’s. *, P 0.05; **, P
0.01; vs. wild-type, , P  0.01 vs. pR5 (n  7–12 animals/group).
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energy homeostasis or oxidative stress levels was evident, sug-
gesting an efficient compensatory machinery within brain cells
at this age.
However, as the mice aged, impairment of OXPHOS and
mitochondrial enzyme activities was aggravated, especially in the
presence of both plaques and tangles. Indeed, despite compen-
satory mechanisms—increased complex I content and CS activ-
ity—the defects of complex I and IV became more marked at 12
months, indicating a failure to restore the bioenergetic ho-
meostasis in tripleAD mice as they age. Then, we also observed a
difference in oxygen consumption between APP/PS2 and
tripleAD mice as well as a drop in ATP levels, with the strongest
decrease found in tripleAD, again suggesting a synergistic action
of the 2 lesions on mitochondria. These mitochondrial defects
were associated with an increase of superoxide anion, as well as
cytosolic ROS levels in 12-month-old APP/PS2, and were most
pronounced in tripleAD mice, suggesting that at this older age
detoxifying mechanisms fail to balance increased ROS produc-
tion, which in turn might further damage mitochondrial
OXPHOS.
In agreement with our functional data, iTRAQ MS identified
3 deregulated subunits of complex I in tripleAD mice: NUCM,
NUIM, and NIDM. NUCM likely has a central role within the
catalytic core of mitochondrial complex I (26). Interestingly,
NUCM and NIDMwere up-regulated in tripleAD brain, probably
as a compensatory response to the functional failure of OX-
PHOS. These data nicely correspond with the detected increase
in complex I content (detected by HAR activity). Inversely,
NUIM, which is thought to participate in the electron transfer
and proton-pumping activities of complex I, is down-regulated in
tripleAD mice. Together, these findings emphasize that A and
tau synergistically impair complex I function with aging. On the
contrary, changes in the expression of complex IV subunits seem
to be mainly related to A. Indeed, a down-regulation of several
subunits of complex IV is essentially seen between pR5 and
tripleAD mice, but not between APP/PS2 and tripleAD mice.
Furthermore, our findings of a mitochondrial dysfunction in
tripleAD mice are supported by a significant deregulation of
mitochondria-related proteins: calmodulin, a small, ubiquitous
Ca2-binding protein, and its putative target, the transmem-
brane proteolipid pore of the vacuolar or vesicular ATPase
(V-ATPase V0) sector subunit a1, with calmodulin functioning
in an ATPase V (0)-dependent manner at synapses (27). Inter-
estingly, both proteins are deregulated in tripleAD mice. Dereg-
ulation of proteins with expression in glial cells, e.g., myelin basic
protein, may indicate additional damage of nonneuronal cells.
However, because expression of A and tau in our mousemodels
is neuron-specific, mitochondria from neurons likely represent
the primary toxic target, but with disease progressing, cells in the
vicinity are likely to be also impacted and damaged.
Our findings are in line with recent studies associating A and
tau with oxidative stress (17, 18, 28). Moreover, APP transport
was shown to be impaired by elevated tau, suggesting a possible
link of the 2 proteins (28, 29). Oligomeric A can attach to tau
(30, 31), causing a rapid dissociation of tau from microtubules
and a collapse of axonal structures leading initially to synaptic
malfunction and ultimately, neuronal death. Interestingly, A
may not only be located to the cell surface but also directly
interact with mitochondria (20) as it can be imported into
mitochondria via the translocase of the outer membrane (TOM)
machinery (32). A crucial role for mitochondria in AD is further
underpinned by findings linking maternal inheritance of mito-
chondrial DNA to both predisposition of AD and glucose
hypometabolism (33) that may reflect energy disturbances as
found, e.g., in our tripleAD model.
Together, our studies highlight the key role of mitochondria in
AD pathogenesis, and the close interrelationship of this or-
ganelle and the two main pathological features of the disease.
This was obtained by combinatorial transgenesis, quantitative
proteomics, and functional assays. We show that disturbances in
the respiratory and energy system of tripleAD mice are due to (i)
a convergence of A and tau on mitochondria, accelerating
defects in respiratory capacity, and (ii) a main defect in mito-
chondrial complexes I and IV. Moreover, we found (iii) that
age-related oxidative stress may exaggerate the dysfunctional
energy metabolism in a vicious cycle, finally leading to cell death.
Our data complement those obtained in a second tripleTG mouse
model (34). They may contribute to a better understanding of
these biochemical pathways and assist in the development of
antioxidative treatments. Importantly, we could reveal defects of
mitochondrial respiratory capacity and a failure to restore
energy homeostasis in mice with plaques and tangles in vivo,
consolidating the idea that a synergistic effect of tau and A
augments the pathological deterioration of mitochondria.
Materials and Methods
Mice Used for the Studies. Four strains of mice were investigated: single-
transgenic pR5 (7), double-transgenic APP/PS2 (6), a crossbreeding (tripleAD)
(11), and nontransgenic wild-type littermate controls. For the proteomic
analysis, 6 female mice were killed from each strain at 10 months of age, and
forebrains dissected. For the functional studies, 7–12 female mice were killed
from each strain at the age of 2, 4, 8, 12, and 16 months to identify the age
when functional changes start, and forebrains dissected (see SI Methods and
Table S2 for details).
Proteomic Approach. Crude synaptosomal preparations of forebrains from
freshly killed mice were obtained for proteomic studies. The proteins were
labeled using the iTRAQ technique and separated by both reverse-phase and
strong cation exchange HPLC. Data were acquired by NanoLC-ESI MS/MS mass
spectrometry and submitted to ProteinPilot for processing (see SIMethods for
all details).
Cellular Analysis. Brain cells were obtained to determine mitochondrial func-
tion. The membrane potential of the inner mitochondrial membrane was
measured using the dye tetramethylrhodamine ethyl ester (TMRE) and the dye
rhodamine 123 (R123) (4). ATP content was determined using a biolumines-
cence assay (ViaLighTM HT; Cambrex Bio Science) (14). The total amount of
mitochondria was measured using the cell-permeable mitochondria-selective
dye. Finally, levels of ROS were measured using the fluorescent probe H2DCF-
DA, and levels of superoxide anion radical using DHE (see SI Methods for all
details).
Studies of Isolated Mitochondria. Mitochondria were isolated from mouse
forebrains to investigate mitochondrial OXPHOS and respiratory capacity.
Mitochondrial oxygen consumption was measured at 37 °C using an Oroboros
Oxygraph-2k system (4, 21). Several mitochondrial enzyme activities (complex
I, complex IV, and citrate synthase) were examined (13, 21) (see SIMethods for
details).
Statistical Analysis. For statistical comparison in functional studies, Student’s
t test, one-way ANOVA followed by Tukey’s post hoc test, and 2-way ANOVA
followed by Bonferroni post hoc tests only for the oxygen consumption
protocol, were used. Only P values 0.05 were considered as statistically
significant. Data are represented as means  SEM.
For iTRAQ statistics, P values were calculated for each protein ratio re-
ported in the Pro Group™ Algorithm Results using ProteinPilot™ Software
(Applied Biosystems). To be considered as significantly deregulated, iTRAQ
ratios had to satisfy the criterion P value 0.01 and 0.82  iTRAQ ratio  1.2
(see SI Methods for all details).
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